Industry News: Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar - Join them here

Industry News: UNC lands $40M to make personalized cancer vaccines using AI

Industry News: The first-ever personalized neoantigen cancer vaccine to pass a phase 3 trial just beat Keytruda alone

Industry News: Moderna shares jump 175% on skin cancer trial success

End of the 3rd Annual Personalized Cancer Vaccine Summit

End of the 3rd Annual Personalized Cancer Vaccine Summit

4:40 pm - Thursday 3rd December 2026